TPST Tempest Therapeutics Inc
Price (delayed)
$1.24
Market cap
$31.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.6
Enterprise value
$20.39M
Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct
Highlights
The EPS has grown by 33% YoY and by 7% from the previous quarter
Tempest Therapeutics's debt has decreased by 6% YoY
The quick ratio is down by 29% since the previous quarter but it is up by 4.9% year-on-year
The net income has contracted by 7% from the previous quarter but it has grown by 4.6% YoY
The equity has contracted by 18% from the previous quarter
Key stats
What are the main financial stats of TPST
Market
Valuations
Earnings
Shares outstanding
25.21M
Market cap
$31.26M
Enterprise value
$20.39M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.63
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$30.26M
EBITDA
-$28.2M
Free cash flow
-$25.78M
Per share
Balance sheet
Liquidity
EPS
-$1.6
Free cash flow per share
-$1.14
Book value per share
$0.76
Revenue per share
$0
TBVPS
$1.87
Total assets
$42.17M
Total liabilities
$25.23M
Debt
$20.26M
Equity
$16.94M
Working capital
$16.99M
Debt to equity
1.2
Current ratio
2.17
Quick ratio
2.14
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-78.3%
Return on equity
-201.1%
Return on invested capital
-136.7%
Return on capital employed
-109.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TPST stock price
How has the Tempest Therapeutics stock price performed over time
Intraday
-0.8%
1 week
-3.88%
1 month
-18.95%
1 year
129.8%
YTD
-71.82%
QTD
-43.38%
Financial performance
How have Tempest Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.66M
Net income
-$31.75M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 7% from the previous quarter but it has grown by 4.6% YoY
The company's operating income fell by 7% QoQ but it rose by 3.3% YoY
Growth
What is Tempest Therapeutics's growth rate over time
Valuation
What is Tempest Therapeutics stock price valuation
P/E
N/A
P/B
1.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 33% YoY and by 7% from the previous quarter
The equity has contracted by 18% from the previous quarter
The price to book (P/B) is 4.1% lower than the 5-year quarterly average of 1.7
Efficiency
How efficient is Tempest Therapeutics business performance
TPST's return on invested capital is down by 18% since the previous quarter and by 4.7% year-on-year
The ROE has grown by 13% from the previous quarter and by 8% YoY
The company's return on assets fell by 4.4% YoY
Dividends
What is TPST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TPST.
Financial health
How did Tempest Therapeutics financials performed over time
The company's total assets is 67% higher than its total liabilities
The company's total assets rose by 37% YoY but it fell by 5% QoQ
The current ratio has declined by 31% since the previous quarter
Tempest Therapeutics's debt is 20% more than its equity
The debt to equity has dropped by 72% year-on-year but it is up by 21% since the previous quarter
The equity has contracted by 18% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.